KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Income from Continuing Operations for 9 consecutive years, with 245845000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 1017.5% year-over-year to 245845000.0, compared with a TTM value of 263861000.0 through Dec 2025, up 396.87%, and an annual FY2025 reading of 263861000.0, up 396.87% over the prior year.
  • Income from Continuing Operations was 245845000.0 for Q4 2025 at Biocryst Pharmaceuticals, up from 12899000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 245845000.0 in Q4 2025 and bottomed at 170426000.0 in Q4 2023.
  • Average Income from Continuing Operations over 3 years is 506000.0, with a median of 12674000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations skyrocketed 84.28% in 2024, then soared 1017.5% in 2025.
  • Year by year, Income from Continuing Operations stood at 170426000.0 in 2023, then surged by 84.28% to 26795000.0 in 2024, then skyrocketed by 1017.5% to 245845000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BCRX at 245845000.0 in Q4 2025, 12899000.0 in Q3 2025, and 5085000.0 in Q2 2025.